Ocular features of Fabry disease: Diagnosis of a treatable life-threatening disorder

被引:63
作者
Samiy, Nasi [1 ]
机构
[1] Retina Inst Carolinas, Charlotte, NC 28207 USA
关键词
cornea verticillata; Fabry disease; lens opacities; lysosomal enzyme;
D O I
10.1016/j.survophthal.2008.04.005
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Fabry disease is a rare, life-threatening, and under-diagnosed disease, with distinctive ocular manifestations identifiable during a routine eye examination. The disease is caused by an inherited deficiency of the lysosomal enzyme a-galactosidase A, resulting in progressive accumulation of glycosphingolipids throughout the body. Long-term clinical manifestations include renal failure, early stroke, and cardiomyopathy. Recently, enzyme-replacement treatment has become available, heightening the importance of early diagnosis so that treatment can be initiated before irreversible organ damage. Ocular manifestations of Fabry disease include cornea verticillata (whorl-like radial lines emanating from a single vortex, Visible on slit-lamp examination), distinctive lenticular opacities, and vascular tortuosity of the conjunctiva and retina. A heightened awareness of Fabry disease among ocular professionals could greatly reduce diagnostic delays and thus reduce the morbidity and mortality of the disease.
引用
收藏
页码:416 / 423
页数:8
相关论文
共 48 条
[1]  
ANDERSEN MVN, 1994, ACTA OPHTHALMOL, V72, P635
[2]   Gastrointestinal manifestations of Fabry disease: Clinical response to enzyme replacement therapy [J].
Banikazemi, M ;
Ullman, T ;
Desnick, RJ .
MOLECULAR GENETICS AND METABOLISM, 2005, 85 (04) :255-259
[3]   Agalsidase-beta therapy for advanced Fabry disease - A randomized trial [J].
Banikazemi, Maryam ;
Bultas, Jan ;
Waldek, Stephen ;
Wilcox, William R. ;
Whitley, Chester B. ;
McDonald, Marie ;
Finkel, Richard ;
Packman, Seymour ;
Bichet, Daniel G. ;
Warnock, David G. ;
Desnick, Robert J. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) :77-86
[4]   Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course [J].
Branton, MH ;
Schiffmann, R ;
Sabnis, SG ;
Murray, GJ ;
Quirk, JM ;
Altarescu, G ;
Goldfarb, L ;
Brady, RO ;
Balow, JE ;
Austin, HA ;
Kopp, JB .
MEDICINE, 2002, 81 (02) :122-138
[5]   Clinical benefit of enzyme replacement therapy in Fabry disease [J].
Breunig, F ;
Weidemann, F ;
Strotmann, J ;
Knoll, A ;
Wanner, C .
KIDNEY INTERNATIONAL, 2006, 69 (07) :1216-1221
[6]  
Chong EM, 1997, CORNEA, V16, P592
[7]   Retinal and choroidal vascular changes in heterozygous Fabry disease [J].
Dantas, MA ;
Fonseca, RA ;
Kaga, T ;
Yannuzzi, LA ;
Spaide, RF .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2001, 21 (01) :87-89
[8]   Enzyme replacement therapy in Anderson-Fabry's disease:: beneficial clinical effect on vital organ function [J].
De Schoenmakere, G ;
Chauveau, D ;
Grünfeld, JP .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (01) :33-35
[9]   Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy [J].
Desnick, RJ ;
Brady, R ;
Barranger, J ;
Collins, AJ ;
Germain, DP ;
Goldman, M ;
Grabowski, G ;
Packman, S ;
Wilcox, WR .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (04) :338-346
[10]  
Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733, DOI DOI 10.1036/ommbid.181